The Influence of Obesity and Insulin Sensitivity on Reward Processing and Decision Making (No acronym)
24 août 2026 mis à jour par: Mary Elizabeth Baugh, Virginia Polytechnic Institute and State University
Reward learning and decision-making processes, which operate largely outside of conscious control, shape food choices and eating behaviors.
Excess adiposity is associated with differences in brain structure and functional connectivity underlying these processes, and insulin resistance, which commonly co-occurs with excess adiposity, has been linked with dopamine signaling that is crucial for these processes.
However, whether and how excess adiposity and insulin resistance affect reward learning and decision-making remains poorly understood.
This study will address that gap, examining the effects of excess adiposity and insulin resistance, and their interaction, on processes of reward learning and decision-making in food-specific and general contexts.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
50
Phase
- N'est pas applicable
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- 18 to 45 years of age
- Self-reported weight stable (within 5 lbs) for previous 3 months
- Not pregnant or planning to become pregnant during study participation
- Weigh more than 110 lbs (due to blood draws used in study)
- Residing in Roanoke, VA, area and/or willing to attend sessions at the Fralin Biomedical Research Institute
Exclusion criteria:
- BMI < 18.5 or > 40 kg/m2
- Hemoglobin A1c > 6.4%
- Fasting blood glucose > 126 mg/dL
- 2-hour blood glucose > 200 mg/dL
- Self-reported current diagnosis of diabetes or other endocrine/metabolic disorder
- Self-reported current inhaled nicotine use
- Self-reported history of alcohol dependence
- Self-reported use of medications known to influence study measures (including antiglycemic agents, thyroid medications, etc.)
- Self-reported neurological or psychological disorder
- Self-reported claustrophobia or discomfort with mock fMRI training
- Self-reported history of head injury resulting in loss of consciousness for more than 10 minutes
- Contraindications to MRI, including pacemaker, aneurysm clip, neurostimulator, cochlear implant, metal in eyes, steel worker, other implants
- Self-reported previous metabolic/weight loss surgery
- Self-reported adherence to special or restrictive diet within the past 3 months (e.g., low-carb, ketogenic, exclusion of food groups/specific macronutrients, etc.)
- Self-reported allergy to ingredient used in the study drinks
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Conditioned Stimulus- First, Then Conditioned Stimulus +
Participants will consume the Conditioned Stimulus (CS) - experimental drink 6 times during flavor-nutrient conditioning sessions.
Then, they will consumes the CS+ experimental drink 6 times during flavor-nutrient conditioning sessions.
|
Participants will consume flavored beverage solutions sweetened with sucralose during 6 conditioning sessions.
Participants will consume flavored beverage solutions sweetened with sucralose and containing 110 calories of maltodextrin during 6 conditioning sessions.
|
|
Expérimental: Conditioned Stimulus + First, Then Conditioned Stimulus -
Participants will consume the Conditioned Stimulus (CS) + experimental drink 6 times during flavor-nutrient conditioning sessions.
Then, they will consumes the CS- experimental drink 6 times during flavor-nutrient conditioning sessions.
|
Participants will consume flavored beverage solutions sweetened with sucralose during 6 conditioning sessions.
Participants will consume flavored beverage solutions sweetened with sucralose and containing 110 calories of maltodextrin during 6 conditioning sessions.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rated Liking
Délai: On the first day of enrollment to the post-test session approximately 1-2 weeks later
|
Participants will rate liking of flavors that will be paired with conditioned stimulus (CS) + and CS- drinks on a labeled hedonic scale during an enrollment session.
In a post-test session, after all conditioning sessions have occurred, participants will rate liking of flavors that were previously paired with CS+ and CS- drinks.
|
On the first day of enrollment to the post-test session approximately 1-2 weeks later
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rated Wanting
Délai: On the first day of enrollment to the post-test session approximately 1-2 weeks later
|
Participants will rate wanting of flavors that will be paired with conditioned stimulus (CS) + and CS- drinks on a visual analog scale during an enrollment session.
In a post-test session, after all conditioning sessions have occurred, participants will rate wanting of flavors that were previously paired with CS+ and CS- drinks.
|
On the first day of enrollment to the post-test session approximately 1-2 weeks later
|
|
Proportion Correct on a Probabilistic Learning Task
Délai: Approximately 30-45 minutes during the enrollment/screening session at the start of the study
|
Participants will complete a probabilistic learning task in which they choose between abstract stimuli and observe probabilistic outcomes with the goal of maximizing accuracy.
The proportion of trials in which the objectively optimal choice has been selected will be computed as the proportion correct.
|
Approximately 30-45 minutes during the enrollment/screening session at the start of the study
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 septembre 2026
Achèvement primaire (Estimé)
1 juillet 2029
Achèvement de l'étude (Estimé)
1 juillet 2029
Dates d'inscription aux études
Première soumission
28 mai 2026
Première soumission répondant aux critères de contrôle qualité
5 juin 2026
Première publication (Réel)
10 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
25 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 août 2026
Dernière vérification
1 août 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 26-058
- K01DK142002 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .